NewLink Genetics Corp (NASDAQ:NLNK)’s share price was down 10.5% on Friday . The stock traded as low as $8.95 and last traded at $10.06. Approximately 2,652,600 shares were traded during mid-day trading, an increase of 80% from the average daily volume of 1,470,033 shares. The stock had previously closed at $9.10.
Several equities analysts have weighed in on NLNK shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $26.00 target price on shares of NewLink Genetics in a research report on Thursday, November 2nd. Zacks Investment Research downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Thursday. Robert W. Baird raised NewLink Genetics from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $8.00 to $22.00 in a research report on Friday, September 8th. Stifel Nicolaus boosted their price objective on NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Finally, Jefferies Group lowered their price objective on NewLink Genetics from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $23.29.
The stock has a market capitalization of $326.00, a price-to-earnings ratio of -3.69 and a beta of 1.10.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3127693/newlink-genetics-nlnk-trading-down-10-5.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.